Vinpocetine
Producer: JSC Irbit Chemical and Pharmaceutical Plant Russia
Code of automatic telephone exchange: N06BX18
Release form: Firm dosage forms. Tablets.
General characteristics. Structure:
Active agent: Vinpocetine of 5 mg.
Excipients - lactose (sugar milk), starch, silicon dioxide colloid (aerosil), talc (magnesium hydrosilicate), magnesium stearate.
Description. Tablets of color, white or white with a yellowish shade, a ploskotsilindrichesky form with risky and a facet.
Pharmacological properties:
Pharmacodynamics. Improves metabolism of a brain, increasing consumption of glucose and oxygen brain tissue. Increases resistance of neurons to a hypoxia; strengthens glucose transport to a brain, through a blood-brain barrier; transfers process of disintegration of glucose to energetically more economical, aerobic way; selectively blocks Sa 2+ - dependent phosphodiesterase; increases levels of adenosinemonophosphate, a cyclic guanozinmonofosfat and adenosinetriphosphate of a brain. Strengthens exchange of noradrenaline and serotonin of a brain; stimulates the ascending branch of noradrenergichesky system, has antioxidant effect. Reduces aggregation of thrombocytes and the increased viscosity of blood; increases the deforming ability of erythrocytes and blocks utilization by adenosine erythrocytes; promotes increase in return by oxygen erythrocytes. Increases a cerebral blood stream; reduces resistance of vessels of a brain without essential change of indicators of system blood circulation. Does not render effect of "burglarizing" and strengthens blood supply, first of all, in ischemic sites of a brain. Gets through a placental barrier.
Pharmacokinetics. It is quickly soaked up. Time of achievement of the maximum concentration in a blood plasma – 1 hour. Absorption happens, mainly, in proximal departments of digestive tract. When passing through a wall of intestines is not exposed to metabolism. The maximum concentration in fabrics is noted in 2-4 hours after intake. Communication with proteins - 66%, bioavailability at intake – 7%. The clearance of 66,7 l/h, exceeds the plasma volume of a liver (50 l/h) that demonstrates extrahepatic metabolism. At repeated receptions the kinetics has linear character. An elimination half-life at the person of 4,83± 1,29 h. It is removed by kidneys and through intestines in the ratio 3:2.
Indications to use:
- reduction of expressiveness of neurologic and mental symptoms at various forms of insufficiency of cerebral circulation (including a recovery stage of an ischemic and hemorrhagic stroke, an effect of the had stroke; tranzitorny ischemic attack; vascular dementia; vertebrobazilyarny insufficiency; atherosclerosis of vessels of a brain; posttraumatic and hypertensive encephalopathy);
- chronic vascular diseases of a choroid and retina of an eye;
- decrease in hearing of perceptual type, Menyer's disease, idiopathic sonitus.
Route of administration and doses:
Inside, after food, 3 times a day. The initial daily dose makes 15 mg. Maximum daily dose of 30 mg. Duration of a course of treatment up to 3 months. At diseases of kidneys and a liver drug is appointed in a usual dose.
Features of use:
Existence of a syndrome of the prolonged interval of QT and administration of drugs causing lengthening of an interval of QT demands periodic control of an ECG. In case of a lactose intolerance it is necessary to consider that lactose is a part of drug. There are no data on influence of a Vinpocetine on ability to driving and performance of work demanding speed of psychomotor reactions.
Side effects:
From cardiovascular system: change of an ECG (ST depression, lengthening of an interval of QT), tachycardia, premature ventricular contraction, lability of arterial pressure, feeling of inflows.
From the central nervous system: sleep disorders (sleeplessness or the increased drowsiness), dizziness, a headache.
From system of digestion:: dryness in a mouth, nausea, heartburn.
Others: allergic reactions, the general weakness, the increased sweating.
Interaction with other medicines:
Interaction is not observed at simultaneous use with β-blockers ((((((((((хлоранолол, Pindololum), Clopamidum, glibenclamide, digoxin, atsenokumaroly and Hydrochlorthiazidum, Imipraminum
Simultaneous use of a Vinpocetine and α-Methyldopums sometimes caused some strengthening of hypotensive effect therefore at such treatment regular control of arterial pressure is required.
Despite the absence of the data confirming a possibility of interaction it is recommended to show care at co-administration with drugs of the central, antiarrhythmic and anticoagulating action.
Contraindications:
- the acute phase of a hemorrhagic stroke expressed to coronary heart disease, the expressed arrhythmias, hypersensitivity to any of drug components.
- pregnancy (perhaps placental bleeding and spontaneous abortions probably as a result of strengthening of placental blood supply).
- the lactation period (at use of drug it is necessary to stop breastfeeding).
- children up to 18 years (in connection with insufficiency of data).
Overdose:
Symptoms: strengthening of expressiveness of side effects.
Treatment: gastric lavage, reception of absorbent carbon, symptomatic therapy.
Storage conditions:
In the dry, protected from light place. To store in the place, unavailable to children. Period of validity 2 years. Not to use after the period of validity specified on packaging.
Issue conditions:
According to the recipe
Packaging:
Tablets of 5 mg. On 10 tablets in a blister strip packaging. 2 or 5 blister strip packagings together with the application instruction in a pack from a cardboard.